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Summary 
 
Glioblastoma multiforme is the most common and most fatal primary brain tumor in 
adults. Despite using advanced conventional therapeutic approaches like surgical 
resection, radiotherapy and chemotherapy only marginal improvement with a median 
survival of about 14 months is observed. Thus, finding urgent novel therapeutic strategies 
to target and kill GBM cells are desperately needed. In this respect, gene therapy provides 
new perspectives for treating cancer, although the safety and efficient delivery of genes 
into target cells still need critical evaluation in further experiments. In particular, 
oncolytic viruses are of interest due to their ability to infect and replicate in tumor cells.  
In this thesis, we analyzed the toxicity and efficiency of Vesicular stomatitis virus 
(VSV)-based oncolytic virotherapy for the treatment of GBM. Vesicular stomatitis virus 
(VSV) has the potential to significantly improve the prognosis of aggressive 
malignancies such as brain cancer but its intrinsic neurotoxicity limited clinical 
development so far. The cytopathogenicity of vesicular stomatitis virus (VSV) has been 
attributed mainly to the glycoprotein of VSV (VSV-G). By exchanging the VSV-G with a 
glycoprotein from a different virus, the tropism of the virus could be changed. Thus, the 
glycoprotein from the Lymphocytic choriomeningitis virus (LCMV-GP) was used for 
pseudotyping VSV as this virus is not neurotoxic. 
By analyzing mouse brains infected with either VSV wild-type or VSV pseudotyped 
with LCMV-GP, it was obvious that VSV-WT induced a strong inflammatory response 
mainly consisting of CD3 positive lymphocytes and CD11b positive microglia cells. In 
contrast, VSV-GP infected brains showed no significant increase in inflammation 
compared to PBS injected control mice. Further, our results from immunostaining with 
Caspase-3 and TUNEL assays demonstrated significantly more apoptotic brain cells in 
the VSV-WT compared to the VSV-GP group.  By using confocal microscopy analysis 
we verified that VSV-WT infected mainly neurons, while VSV-GP did not show 
infection of brain cells at all. Intravenous injection of VSV-GP virus into mice that 
harbored, intracerebral U87 gliomas lead to specific infection of the glioma cells, while 
normal brain cells were spared.  
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In conclusion, replication-competent VSV-GP vectors are promising vehicles for future 
gene therapy of brain cancer as they specifically and efficiently infect brain tumor cells 
and do not induce a neurotoxic damage to the normal brain tissue.   
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1 Introduction 
 
1.1 Cancer and cancer development 
Cancer is defined as a group of diseases characterized by uncontrollable abnormal cell 
growth and division, leading to formation of malignant tumors. Tumor cells can further 
spread from the primary tumor to other organs/lymph nodes through the blood and 
lymphatic vessels to establish metastatic disease. 
The knowledge of many aspects of cancer has increased substantially in the last 
decades, which has improved treatment options for some cancers. However, many 
molecular mechanisms mediating tumor initiation and progression are still unclear. 
According to a review published by Hanahan and Weinberg all cancers have six 
common hallmarks. These hallmarks describe a series of abilities that a normal cell must 
acquire to transform into a cancer cell. These are unlimited replicative potential, evasion 
of growth inhibitory signals, autonomy of growth signals, resistance to apoptotic signals, 
ability to promote angiogenesis and to invade other tissues or metastasize (1). Recently, 
Hanahan and Weinberg published an updated version of the hallmarks of cancer adding 
two new ones, the ability to escape from immune attacks and deregulated metabolism in 
order to sustain continued growth (2). 
 
1.1.1 Oncogenes and tumor suppressor genes 
The phrase “Cancer is a genetic disease at the cellular level” is a good description for 
cancer provided by Lauren Pecorino (3). Thus, similarly to all genetic diseases, DNA 
alteration or mutation is the main reason for causing cancer (3). DNA mutations may 
arise either spontaneously or may be caused by environmental factors. The cancer-critical 
genes are divided into two broad categories: oncogenes and tumor suppressor genes. 
Oncogenes are growth-promoting genes often mutated or amplified in cancer leading to 
production of a higher amount of protein and therefore act in a dominant manner for 
tumor formation. Dominant means a mutation in one allele is enough for cancer 
development (3). Tumor suppressor genes work in the opposite way. They encode 
proteins that inhibit cell growth and tumor formation. Tumor suppressor mutations are 
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recessive, which means that both alleles of the gene must be mutated to induce an effect 
(3). The first discovered and one of the most crucial tumor suppressor proteins is protein 
53 (p53) encoded by the tumor protein 53 (TP53) gene (4, 5). TP53 gene is mutated 
almost in 50 % of cancers. P53 plays an anticancer role in the body, as it initiates 
programmed cell death in case of damaged DNA. Further it can provide genomic stability 
and inhibition of angiogenesis (6). 
 
1.1.2 Angiogenesis 
For receiving nutrients and oxygen and for disposal of metabolic waste products, tumor 
cells rely on blood vessels as normal cells do. When tumors enlarge beyond a certain 
size, the cells residing in the core of the tumor mass will not get sufficient oxygen and 
nutrients. As a consequence they will get hypoxic and upregulate Hypoxia Inducible 
Factor-1α (HIF1α). HIF1α is a gene regulatory protein, which enables the cells to cope 
with lower oxygen and nutrient levels by activating transcription of pro-angiogenic 
factors such as vascular endothelial growth factor (VEGF) (7-10). VEGF is a signal 
protein that stimulates proliferation of endothelial cells to form new blood vessels and 
thereby initiate angiogenesis (8). 
 
1.1.3 Metastasis 
Metastasis is the most fatal aspect of cancer, which is responsible for 90% of cancer-
associated deaths (8). The metastatic process is started with entering of tumor cells into 
the blood or/and lymphatic vessels by crossing the basal lamina and the endothelial lining 
of the vessels. Tumor cells that entered lymphatic vessels get access to lymph nodes and 
give rise to lymph-node metastases (8). Tumor cells which have entered the bloodstream 
are transported with the blood flow and finally get trapped in other organs and start to 
establish new tumors at these distant sites (8, 11). Change in expression of the cell 
adhesion molecules, ability to escape from the body’s immune system and activation of 
enzymes that break down the extracellular matrix are important factors which are 
necessary to establish metastatic disease (11). 
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1.2 Brain cancer 
A brain cancer is an intracranial solid neoplasm, either primary by developing in the 
brain and adjacent structures or a metastasis from a different organ. 
The most common primary brain tumors are: 
§ Gliomas  
§ Meningiomas 
§ Pituitary adenomas  
§ Nerve sheath tumors (tumors of cranial and spinal nerves) 
 
Primary brain cancer originates from the main cell types, which are resident in the brain 
and are used for classification of the central nervous system tumors. Thus, gliomas are 
arising from glial cells of the brain and can be subdivided into astrocytomas, 
oligodendrogliomas and ependymomas (12). Astrocytomas and in particular 
glioblastoma, the most malignant astrocytoma, are the most frequent gliomas. Gliomas 
are classified by the World Health Organization (WHO) based on the level of 
malignancy. According to the WHO, a benign astrocytoma is a grade I tumor and the 
most malignant astrocytoma, glioblastoma, is a grade IV tumor. At least 50 % of all 
gliomas and 12-15 % of all primary intracranial tumors are glioblastoma (13). 
 
1.2.1 Glioblastoma multiforme (GBM) 
The annual incidence of glioblastoma multiforme (GBM) varies between 3 – 6 per 
100,000 people (14). 
Some risk factors are defined for glioblastoma:  
§ Ionizing radiation  (15) 
§ Sex: for unknown reasons, GBM occurs more commonly in males (3:1) 
§ Age: the incidence rate increases with age 
§ Ethnicity: caucasian origin are diagnosed more often with GBM 
§ A history of low-grade astrocytema  
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§ Familial tumor syndromes: Li-Fraumeni syndrome, Turcot syndrome, tuberous 
sclerosis and neurofibromatosis are associated with an increased risk of developing 
GBM (16) 
 
After several decades of intensive research, molecular studies confirm certain patterns of 
mutations, which are present in varying proportions of GBMs. Frequent genetic 
alterations in human GBMs include dysregulation of growth factor signaling via 
amplification and mutational activation of receptor tyrosine kinase (RTK) genes, in 
particular of EGFR; activation of the phosphatidylinositol-3-OH kinase (PI (3)K) 
pathway and inactivation of the p53 and retinoblastoma tumor suppressor pathways (17). 
Despite improvement in understanding of the molecular changes, the prognosis of GBM 
patients is still dismal. 
 
1.3 Therapy 
1.3.1 Conventional therapy 
A couple of factors complicate GBM treatment including resistance of brain tumor cells 
to conventional therapy, damage and low repair capacity of brain cells as well as the 
blood-brain barrier which represents a penetration problem for drugs (18, 19). 
The first stage of glioblastoma treatment involves neurosurgical resection of the 
tumor followed by radiotherapy, chemotherapy and recently also anti-angiogenic therapy. 
However, long-term tumor control is impossible, because all malignant gliomas are 
highly infiltrative with single tumor cells invading into the cortex and migrating along 
white matter tracts. These cells escape conventional therapies. Therefore, prognosis for 
GBM patients is still poor, with a median survival time about 14 months (20). The dismal 
prognosis of glioblastoma encourages researchers to find new treatment modalities for 
malignant gliomas. Molecular targeted therapy, immunotherapy and virotherapy/gene 
therapy are novel therapeutic approaches in the treatment of GBM. As gene therapy is the 
focus of the present thesis, this subject will be introduced in detail in the following 
paragraphs. 
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1.3.2 Gene therapy 
Gene therapy can be defined as the use of nucleic acids as drugs. The combination of 
virus-based methods (1960s) with recombinant DNA technology (1970s) has established 
a new way in genetic medicine that could potentially compensate for errors in the 
diseases, which are associated with DNA deficiency (21). In the 1980s some pioneer 
research groups used gene therapy to replace various deficient proteins such as arginase 
in children with hyperargininemia and hemoglobin in thalasemia (22). According to the 
data from Journal of gene medicine approximately 1,700 clinical trials have been 
recorded with using a number of techniques for gene therapy (Figure 1.1).  
 
 
 
Figure 1.1. The world wide 
clinical gene therapy trials 
from 1989 to 2012 (23). 
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1.3.2.1 Gene therapy vectors 
In order to deliver genes into target cells, two kinds of vectors can be employed as 
vehicles for gene transfer: 
1. Viral delivery vectors 
2. Non-viral delivery vectors 
An optimal gene delivery system can be described as a system with several important 
functions. The system should efficiently transduce target tissue and ensure gene 
transcription in the cell and at the same time be safe without causing cytotoxic side 
effects. In addition the vector should be easily to manufacture (24). 
From the onset of gene therapy, viral vectors have been recognized as the most 
efficient vehicles for transferring genes to human cells, although non-viral vectors 
showed some advantages as feasibility of large scale production and low host 
immunogenicity.  
 
1.3.2.1.1 Viral delivery systems 
Various classes of viruses have been applied as a tool for gene therapy by using their 
natural ability to enter the genome of the infected cell and introduce their DNA into the 
cell with high efﬁciency (Figure 1.2). Therefore it is possible to take advantage of the 
properties of the virus by introducing an ideal gene into the virus and deliver this gene 
into a target cell (25). 
Using replication defective viral vectors is very important to ensure that the viruses 
used as vectors are safe. By replacing genes which allow virus replication with 
therapeutic genes is defined as replication deficiency. In this regard viral vectors can be 
produced only in special cell lines called “packaging cell lines” (PCLs) (26), which 
harbor the genes for the assembly of the virus and the therapeutic gene on a separate 
plasmid. Viral vectors, with regards to having different replication strategies are 
subdivided in two main categories:  
1. Integrating vectors 
2. Non-integrating vectors 
The difference between integrating viruses and non integrating vectors is that the former 
insert themselves into the recepient’s genome and can therefore be inherited stably to the 
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progeny, for example lentiviral vectors, while the latter form an extrachromosomal 
genetic element, such as adenoviral vectors (24). 
 
 
  
 
 
Figure 1.2. Vectors used in gene therapy clinical trials, 2012 (27). 
 
1.3.2.1.2 Oncolytic viruses 
The concept of oncolytic virotherapy is to employ virus properties enabling to infect and 
eradicate malignant cells while in contrast non-lytic vectors express transgenes that 
generate an anticancer effect. Several oncolytic viruses were used for targeting cancers 
during the 1950s and 1960s (28). One of the first viruses that showed promising results 
was a vaccine strain of rabies virus, which was used for melanomatosis patients (29). 
Further, the oncolytic efficacy of adenovirus serotype (type 4), the flavivirus West Nile 
virus (strain Egypt 101), the paramyxoviruses, mumps and Newcastle disease virus 
(NDV) were confirmed after using them on human tumors (30-32). Despite providing 
promising therapeutic potential in humans, the approach was abandoned due to toxicity 
as the viruses were not selective for tumor cells, but also infected normal cells. Later, 
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researchers took advantage of recombinant technology and made viruses, which were 
selective for tumor cells. The first selective oncolytic virus that was applied for cancer 
therapy in an experimental model was herpes simplex virus type1 (HSV-1) in 1991. In 
1996 the engineered adenovirus Onyx-015 was used in a clinical trial for cancer patients 
(33). 
Currently, oncolytic gene therapy is applied in a broad range of cancers. Based on 
information from a recent study, 7% of the world wide clinical gene therapy trials from 
1990 to 2004 were carried out on GBM patients (34). 
Vector delivery to the tumor cells can be intratumoral, intracavitary, or 
intravascular. Gene products of oncolytic viruses can inhibit growth of residual tumor 
cells after surgery in combination with other therapies (33). 
 
1.3.2.1.2.1 VSV oncolytic viruses 
Vesicular stomatitis virus (VSV) is a virus from the family of Rhabdoiviridae, a common 
laboratory virus used for research purposes and so far the only Rhabdovirus applied in 
cancer targeted therapies (28, 35). VSV causes oral disease in insects, cattle, pigs and 
horses, however is considered to be attenuated in humans. VSV has several serotypes, 
classified as Vesicular stomatitis Indiana virus, Vesicular stomatitis New Jersey virus and 
Vesicular stomatitis Alagoas virus (36). The genome of the virus is a single molecule 
which contains 11.2kb of negative sense RNA (Figure 1.3). Five genes are placed 
between 3′ leader (le) and 5′ trailer (tr) regions in the order 3′-N-P-M-G-L-5, encoding 
five major proteins: Glycoprotein (G), large polymerase (L), phosphoprotein (P), matrix 
(M) and nucleocapsid (N) (Fig 1.3) (37, 38). The glycoprotein (G) resides on the cell 
surface and contains sialic acid, which is necessary for cell surface attachment and 
budding. The nucleocapsid protein (N), the phosphoprotein (P) and polymerase or L 
protein are responsible for viral transcription and subsequently constitute the viral 
genome replication complex. The Matrix or M protein is a multi-functional protein which 
consists of 229 aminoacids. It has an important role in budding and apoptosis. It also acts 
as a critical player in the oncolytic activity of VSV (39). 
VSV has many advantages that make it a promising therapeutic candidate: (1) VSV 
has a short and highly cytolytic replication cycle which kills a wide range of tumor cells 
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rapidly; (2) it is easy to produce and genetically stable which allows generation of high 
titers; (3) it is sensitive to the host antiviral response, which mediates its cancer 
selectivity (40); (4) it is not a human pathogen so there is not any preexisting immunity in 
humans that could limit clinical applications (39, 41-43). 
As of yet, there is not any clinical trials initiated with VSV in cancer patients, 
because VSV is highly neurotoxic, which is one of the disadvantages limiting its 
application in clinical trials (44-46). However, several research groups have attempted to 
develop attenuated viruses (AV). The major concern is that whether AVs would be 
effective enough for treatment (47-49) as the reduction of cytotoxicity of the virus can 
only be achieved by limiting also its replication ability and oncolytic activity (50). 
Since the tropism of a viral vector is determined by its envelope protein which 
interacts with a specific receptor on the cell surface, we can assume that neurotropism of 
VSV is attributed to the glycoprotein (VSV-G) (51-54). The glycoprotein of VSV binds 
to phosphatidylserin (important component of the cell surface membrane), which is 
highly concentrated in myelinated part of neurons (39). 
By exchanging the VSV-G with a glycoprotein from a different virus, the tropism 
of the virus could be changed in order to minimize the neurotropism, but at the same time 
to maximize tropism for tumor cells. This approach will be discussed in the following 
chapter. 
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.  
Figure 1.3. Enveloped, bullet shaped VSV and negative-stranded RNA linear genome of VSV. 
The genome of VSV is about 11 kb in size, which Encodes for 5 distinct proteins: Glycoprotein 
(G), large polymerase (L), phosphoprotein (P), matrix (M) and nucleocapsid (N) (55). 
 
1.3.2.1.2.2 Modification of viral tropism: Pseudotyped VSV 
The exchange of the virus glycoprotein by a glycoprotein from a different virus is called 
pseudotyping and changes the tropism of the chimeric viral particle. Using this strategy, 
VSV can accommodate glycoproteins from other viruses, after mixed infections of cells. 
Consequently, the cell tropism of the novel virus would be determined by the receptor 
specificity of the introduced glycoprotein (56). 
Miletic and Von Laer et al. have in a collaborative effort established several novel 
chimeric viruses that carry the envelope glycoproteins (GP) of the lymphocytic 
choriomeningitis virus (LCMV). They showed that LCMV-GP pseudotypes can be 
efficiently incorporated into the gammaretroviral and lentiviral vector envelope (57, 58). 
These pseudotypes are stable, but unlike the vesicular stomatitis virus G protein, the 
LCMV glycoproteins are not cytotoxic/neurotoxic (59). Moreover, Miletic et al. (2004, 
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2007) showed that LCMV-GP pseudotyped lentiviral vectors delivering a suicide gene 
confirm high transduction efficacy and killing of glioblastoma in a rat glioblastoma 
model (58, 60). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. VSV and VSV / 
LCMV-GP. By reverse genetic 
techniques, the virion 
glycoproteins were changed. 
Consequently, the cell tropism 
of VSV / LCMV-GP would be 
determined by the receptor 
specificity of the interduced 
glycoprotein. 
 
 
Therefore, the LCMV-GP would be an optimal candidate for pseudotyping with VSV in 
order to eliminate neurotropism. The VSV normally packaged with the glycoprotein 
VSV-G, revealed the ability to incorporate the LCMV-GP glycoprotein into the viral 
envelope, generating a pseudotyped virus (VSV-GP; Figure 1.4). The VSV-GP was first 
generated as a replication deficient virus and proved not to infect neuronal cells. In 
addition it was still infecting and killing cancer cells as efficiently as wild-type VSV. 
Hence the oncolytic VSV-GP pseudotypes are currently under development for the 
treatment of melanoma, brain and ovarian cancer (54). 
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2 Aims 
Based on the information provided in the previous sections, the following hypothesis and 
aims are outlined in the presented thesis:  
 
Hypothesis  
Although replication deficient VSV-GP has been proven to be devoid of neurotoxicity 
(54), replication competent virus has to be tested as this will be used as the final 
therapeutic agent in order to maximize the therapeutic effect for glioblastoma treatment. 
By injecting replication competent VSV wild-type (WT) and VSV-GP into the brains of 
normal mice, our collaboration partner showed that VSV-WT even when using low virus 
titers killed the mice, whereas all mice injected with high titers of VSV-GP survived 
(Muik A. et al., unpublished observations). Therefore we hypothesize that VSV-WT due 
to infection of normal brain cells induces a lethal encephalitis, while in contrast VSV-GP 
is sparing normal brain cells and thus is the ideal vector for gene therapy of glioma. 
 
Aim 
Because malignant gliomas only rarely metastasize outside the skull, novel locoregional 
treatment modalities such as gene therapy are potentially interesting. 
The aim of this thesis is to compare neurotoxicity of replication competent wild-type 
VSV and VSV pseudotyped with the non-neurotropic LCMV-GP and to identify whether 
VSV-GP is an attractive candidate for gene therapy of glioma.  
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3 Materials 
 
Table 3.1: chemicals, solutions and reagents  
 
Chemical/solution Catalogue nr. Supplier 
Bovin serum albumin(BSA) A4503 Sigma-Aldrich, St. Louis, 
Missouri, USA 
EDTA  
 
ED2SS Sigma-Aldrich, St. Louis, 
Missouri, USA 
Ethanol, absolute  
 
32221 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Extravidin-Cy3 (1:100) 125K6195 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Fat pen H-4000 Vector laboratories, Inc. 
Burlingame, California, 
USA 
Haemotoxyline RBA-4213-00A CellpathLTd, UK 
Hydrogen peroxide H1009 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Isopentane M3263-1L Sigma-Aldrich, St. Louis, 
Missouri, USA 
Paraformaldehyde (PFA) 
powder  
 
76240 Fluka, Sigma-Aldrich, St. 
Louis, Missouri, USA 
Tissue-Tech O.C.T 
Compound 
90501 Sakura Finetek, USA  
Triton X-100  
 
T8787 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Vectashield Mounting 
Solution w/DAPI  
 
H1200 Vector Laboratories, 
Burlingame, California, 
USA 
Xylenes 33817 Sigma-Aldrich, St. Louis, 
Missouri, USA 
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Table 3.2: Commercial kits 
Article Cataloque number Producer 
DAB detection kit 
 
K3468 DAKO laboratories, CA, 
USA 
In Situ Cell Death Detection 
Kit, POD (peroxidase) 
 
1684817 
Roche applied science, 
Penzberg, Upper Bavaria, 
Germany  
M.O.M kit (peroxidase) 
 
PK-2200 Vector laboratories, Inc. 
Burlingame, CA, USA 
Vectastain ABC kit PK-6200 Vector laboratories, Inc. 
Burlingame, CA, USA 
 
 
 
 
Table 3.3: Buffers/solutions prepared in the lab 
 
Citrate buffer,10 mM (pH=6) 2.94 g Sodium citrate di-hydrate mixed 
with 250 µl Tween 20, pH adjusted with 
HCl, add MilliQ H2O up to 1 liter 
Dulbecco’s Phosphate Buffered Saline 
(PBS) 1x 
 
1 volume of Dulbecco’s Phosphate 
Buffered Saline (10x), 9 volumes of 
autoclaved MilliQ H2O  
Ethanol,96% 96 ml, absolut Ethanol diluted with  
MilliQ H2O up to 100 ml 
 
3% H2O2 0.1 ml 30%hydrogen peroxide to 0.9 ml 
1xPBS 
4% Paraformaldehyde/PBS 40g PFA powder diluted in 1L PBS and 
heated in steamer until it become clear 
Permeabilisation solution for Tunel assay 
 
0.1% Triton X-100, 0.1% sodium citrate 
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Protein/serum block for IHC 950 µl TBST/5% BSA+50 µl serum from 
species secondary antibody 
 
30% Sucrose/PBS 150 g sucrose mixed with 50 ml 10x PBS, 
diluted with MilliQ H2O up to 500 ml 
TBS Tween/buffer (pH=7,2 - 7,6) 50 Mm Tris base,300 Mm NaCl, 0,05% 
Tween 20 was mixed add MilliQ H2O up 
to a total volume of 1 liter, pH adjusted 
with HCl 
 
 
 
 
Table 3.4: Primary antibodies 
Anti-X 
antibody, 
application  
 
Dilution  Source species 
and clonality  
Catalogue nr.  Supplier  
CD3 
 
1:500 Rabbit 
polyclonal IgG 
ab5690 Abcam, 
Cambridge, 
United 
Kingdom  
CD11b 1:300 Rabbit 
polyclonal IgG  
ab75476 Abcam, 
Cambridge, 
United 
Kingdom  
Cleaved         
Caspase-3 
1:50 Rabbit  
Monoclonal 
D175 5A1E Cell signaling 
technology, 
MA,USA 
GFAP 1:200 Mouse 
monoclonal 
IgG1  
MAB3402 Millipore, 
Billerica, MA, 
USA 
NeuN 1:200 Mouse 
monoclonal 
IgG1 
MAB377 Millipore, 
Billerica, MA, 
USA 
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Table 3.5: Secondary antibodies 
 Antibody  
 
Dilution  Source species 
and clonality  
Catalogue nr.  Supplier  
Biotinylated 
anti rabbit IgG  
1:100 Goat anti-rabbit 
IgG 
BA-1000 Vector 
laboratories, 
Inc. 
Burlingame, 
CA, USA 
anti-GFP, 
Alexa Flour 
488 conjugate 
1:200 Rabbit IgG 
fraction, 
polyclonal  
 
A21311 Invitrogen 
laboratories, 
Oregon, USA 
 
 
 
Table 3.6: Hardware 
Name Catalogue nr./Model  Supplier 
Confocal microscope LSM 510 Meta Carl Zeiss Microimaging 
GmbH, Oberkocken, 
Germany  
Cryostate Leica CM3050S Leica Biosystemes, 
Germany 
Fluorescence microscope Axioplan II  Carl Zeiss Microimaging 
GmbH, Oberkocken, 
Germany  
Optical microscope Nikon ECLIPSE, E600 Nikon, Tokyo, Japan 
 
 
 
Table 3.7: Software 
 
Program Version Supplier 
Adobe photoshop CS5 Adobe Systems Inc., San 
Jose, California, USA 
Microsoft Office Excel 2003 Microsoft Corporation , 
Redmond, Washington, 
USA 
NIS-Elements BR Image 
software  
4 Nikon, Tokyo, Japan 
Zeiss LSM Image Examiner 
(LSM 510META) 
4.2 Carl Zeiss Microimaging 
GmbH, Oberkocken, 
Germany 
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4 Methods  
All procedures were performed at room temperature unless otherwise stated. 
 
4.1 Immunostaining of paraffin sections 
3 µm thick sections from paraffin-embedded formalin-fixed tissue were deparaffinized in 
a xylene bath (Sigma-Aldrich, Missouri, USA) for 2x5 minutes, in absolute ethanol 
(Sigma-Aldrich, Missouri, USA) for 2x3 minutes, in 96% ethanol (Table 3.3) for 2x3 
minutes and finally in distilled water for 2 min. For antigen retrieval, depending on the 
primary antibody, sections were heated either Citrate buffer (pH=6, Look at table 3.3) or 
EDTA 1mM (pH=6, Sigma-Aldrich, Missouri, USA) for 5 min in the microwave and 
subsequently in the steamer for 25 min. The sections were then cooled down on the bench 
for 25 min and thereafter put under running water for 10 min. The tissue was encircled 
with a fat pen (Vector laboratories, CA, USA) and TBS w/Tween (Table 3.3) was added 
immediately to avoid tissue drying. The sections were blocked with a mixture of 950 µl 
TBST/5% BSA and 50 µl of serum derived from species of the secondary antibody. The 
sections were incubated with monoclonal antibodies, which were diluted in TBS/5% 
serum (of secondary antibody) and were kept at 4 ºC over night.  
On the second day the sections were rinsed with TBS w/Tween for 2x5 min. A 
solution of 3% H2O2 (0.1 ml 30% hydrogen peroxide to 0.9 ml 1x PBS) was prepared and 
added to the sections for 5 min. A biotinylated antibody (Table 3.5) was used as 
secondary antibody dilution 1:100 in TBS Tween/buffer and incubated with avidin biotin 
complex (ABC) from Vectastain ABC kit (Vector Laboratories, CA, USA) for 30 min at 
room temperature. Peroxidase activity was determined by DAB solution. DAB solution 
was prepared by adding one drop of DAB chromogen substrate to 1 ml of buffered 
substrate (DAKO laboratories, CA, USA). The index was analysed by NIS-Elements BR 
Image software (Version 4, Nikon, Japan). For each slide, ten areas were randomly 
counted at different magnifications. 
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4.2 TUNEL assay 
TUNEL (TdT-mediated dUTP nick end labeling) is a specific technique for labeling 
distinctive size of DNA fragments, which are found in the nuclei of apoptotic cells. In 
this procedure the enzyme terminal deoxynucleotidyl transferase (TdT) adds chains of 
labeled deoxynucleotide to the 3'-OH ends of DNA fragments. 
The brain sections were deparaffinized as described before under the immunostaining 
section. The tissues were encircled with fat pen and pretreated with proteinase K 
(nuclease free, In Situ Cell Death Detection Kit- POD, Roche Applied Science) for 15 
minutes at room temperature. After rinsing three times with PBS (Table 3.3) the 
endogenous peroxidase was inactivated with 3% H2O2 for 7 minutes. Permeabilisation 
solution (0.1% Triton X-100, 0.1% sodium citrate) was freshly prepared and added to the 
tissues for 2 min, while they were kept on ice. Tunel reaction mixture was prepared 
according to the manufacturer's protocol (In Situ Cell Death Detection Kit- POD, Roche 
Applied Science). 100 µl label solution was removed for 2 negative controls and total 
volume of enzyme solution (50 µl) was added to the remaining 450 µl label solution to 
obtain 500 µl Tunel reaction mixture. The slides were incubated with the reaction 
mixture in a humidified chamber at 37°C for one hour, and subsequently washed three 
times with PBS. Sections were incubated with converter-POD (In Situ Cell Death 
Detection Kit- POD, Roche Applied Science) at room temperature for 30 minutes, 
followed by incubation with diaminobenzidine (DAB) solution. Apoptotic cells were 
analyzed using NIS-Elements BR Image software (Version 4, Nikon, Japan). For each 
slide, we randomly counted ten sections, using a light microscope at a magnification of 
×20. The positive cells with condensed chromatin masses, were counted as apoptotic 
cells. 
 
4.3 Snap-Freezing and cryosectioning of tissue samples 
Mouse brains were first fixed in 4% Paraformaldehyde/PBS solution (Table 3.3) 
overnight and then incubated in 30% sucrose/PBS solution (150 g sucrose mixed with 50 
ml 10x PBS, diluted with MilliQ H2O up to 500 ml) for three days at 4 ºC. Coronal slices 
of mouse brains were prepared using tissue scalpels and were positioned on a thick paper 
and coated with Tissue-Tech O.C.T Compound (Sakura Finetek, USA). The tissue was 
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snap-frozen in isopentane (2-methyl butane) chilled with dry ice (-70 ºC) and stored at - 
80 ºC until it was used.  
Serial coronal sections with a thickness of 10 µm were cut on a cryostate. From the 
serial sections, every 10th section was examined under a fluorescence microscope (Carl 
Zeiss, Oberkochen, Germany). Sections that showed green fluorescence, indicating virus 
infection (GFP) were selected for further analysis. Sections were stored in a freezer (- 80 
ºC) until studied. 
 
4.4 Double Immunofluorescence of cryosections 
To investigate which cell types were infected by the viruses, the cryosections were 
stained with antibodies against neurons (NeuN) and astrocytes (GFAP). Anti-GFP 
antibody was used to enhance the GFP signal indicating virus infection. DAPI was used 
to stain nuclei. 
Before staining, the slides were warmed up to 37 ºC for 20 minutes and thereafter 
fixed with 4% paraformaldehyde/PBS (Table 3.3) for 15 min. After washing with PBS 
for 10 min, the tissue was encircled with a fat pen and was blocked with a mixture of IgG 
blocking reagent (M.O.M kit, Vector laboratories, Burlingame, CA, USA) dilute in PBS 
for 1 hour. Thereafter, 200µl protein concentration (M.O.M kit) was mixed with 2.5 ml 
PBS and added to the sections for 5 min. After tipping excess solution off the sections, 
the primary antibodies, NeuN for neurons (1:200 dilution; Millipore, Billerica, MA, 
USA) and GFAP (1:200 dilution; Millipore, Billerica, MA, USA) for astrocytes were 
used. After adding primary antibody, the slides were put into a humidified chamber at 4 
ºC overnight.  
On the next day, sections were washed 3x for 10 min with PBS. Thereafter 
biotinylated anti-mouse IgG (1:250, M.O.M kit) was used as a secondary antibody for 1 
hour. After rinsing with PBS 2x for 10 min, Extravidin-Cy3 (1:100, Sigma-Aldrich, 
Missouri, USA) was added to the sections for 30 min. Finally, the sections were 
incubated with anti-GFP antibody (Invitrogen laboratories, USA) dilute 1:200 in PBS for 
60 min and subsequently washed with PBS 3x for 10 min. For microscopy the sections 
were mounted with a glue containing DAPI (Vector Laboratories, CA, USA). 
 
29 | P a g e  
 
4.5 Confocal imaging  
In confocal or fluorescence microscopy, the specimen is excited by light of different 
wave lengths which is detected by the microscope's camera. In consequence in a regular 
fluorescence microscope we get a big and unfocused background of the image. In 
contrast, the principle of confocal imaging is the use of a pin hole to reject out-of-plane 
unfocused light. In consequence it creates sharp images of a specimen with less 
background. The confocal microscope is equipped with a laser as light source, which has 
the highest intensity, to be detected while all other light is deprived. When light is 
emitted by the specimen and focused through the pin hole it is measured by a detector 
(photomultiplier tube) connected to a computer. Only one point (pixel) in the specimen is 
observed at a time, and the computer builds up an image as a chosen number of pixels 
detected.  
Zeiss LSM 510 Meta (Carl Zeiss, Oberkochen, Germany) located in the Molecular 
Imaging Center (MIC) of department of Biomedicine, Bergen was used for experiments 
performed in this project. Zeiss LSM 510 Meta is equipped with several lasers, of which 
the UV laser was used to excite at 358 nm (DAPI), the Argon laser was used to excite at 
488 nm (FITC) and the HeNe laser was used to excite at 543 nm (Cy3). Pictures were 
taken from areas were green fluorescence (FITC) was observed, indicating virus 
infection. Single pictures as well as stacks, representing serial pictures with different 
depths (z-axis), were taken. Pictures were then analyzed with the Zeiss LSM Image 
Examiner (Version 4.2, Carl Zeiss, Oberkocken, Germany). 
 
4.6 Statistics 
Statistical analysis was carried out using the program Microsoft Office Excel 2003 
(Microsoft Corporation, Redmond, Washington, USA). The student’s t-test was used, and 
a p-value of <0.05 was considered statistically significant. 
 
 
 
 
 
30 | P a g e  
 
5 Results  
5.1 Toxicity and efficiency of oncolytic VSV vectors  
 
 
5.1.1 Histological analysis reveals strong inflammation in VSV-WT injected mice 
 
We received paraffin-embedded brain tissue from our collaborator, who performed the 
injection experiments (Alexander Muik, Frankfurt, Germany). To directly compare the 
neurotoxicity of VSV-WT and VSV-GP, histological slides from either VSV-WT or 
VSV-GP infected mice brains at day 3 and day 7 post infection (p.i.) were stained with 
Hematoxylin and eosin (Figure 5.1). PBS injected animals were used as a control.  Part A 
of Figure 5.1 illustrates the injection tracks of VSV-WT and VSV-GP vectors 
administrated intracerebrally compared to PBS injected controls. VSV-WT shows a 
stronger inflammatory response close to the injection site compared to VSV-GP and PBS, 
both after 3 and 7 days p.i. 
To investigate whether the viruses spread from the injection site to distant areas in the 
brain, we looked at the brain hemisphere contralateral to the injection site (Figure 5.1 B). 
VSV-WT showed perivascular accumulation of inflammatory cells as well as spreading 
of immune cells into brain tissue at both days p.i. Inflammatory cells were often observed 
in direct contact to neurons (Figure 5.2). In contrast, VSV-GP only showed a few single 
inflammatory cells around vessels and no significant inflammation in the brain tissue. 
PBS injected control animals did not show any sign of inflammation. 
Interestingly, in the VSV-WT group there was sign of edema with loosely textured 
brain tissue around the inflammatory spots at day 7 after infection which was not 
observed at day 3 p.i. (Figure 5.1 B). 
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Figure 5.1. H&E stained brain sections of mice injected with VSV-WT, VSV-GP or PBS 
intracerebrally. The upper panel shows the injection tracks (A). The lower panel illustrates the 
contralateral hemisphere (B). Black arrows reveal inflammation around vessels at distant sites 
from injection track. Edema is visible around vessels in VSV-WT after 7 days p.i. ( * ). 
(Magnification: ×20). [Scale bars: 100 µm]. 
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 Figure 5.2. H&E stained brain 
sections of mouse. The injection 
area was avoided. Black arrows 
reveal Inflammatory cells, 
which are in direct contact to 
neurons. The amount of 
inflammatory cells, which were 
in direct contact with neurons 
was high in VSV-WT day 3 p.i.. 
(Magnification: ×40). [Scale 
bars: 100 µm].  
 
 
 
 
5.1.2 Inflammation is composed of CD3 positive T cells and CD11b positive 
microglia 
 
For the following experiments we analyzed brain tissue distant from the injection site in 
order to identify responses that are specific to spread of the virus and not related to 
reactive changes of the injection.  
To identify the type and quantity of immune cells causing the inflammation in VSV-
WT injected animals, we performed immunohistochemistry. Virus infections most often 
induce a T cell mediated immune response and therefore we stained the sections with the 
T cell marker CD3 (Figure 5.3).  VSV-WT brains showed a strong infiltration of CD3 
positive lymphocytes around vessels and in the brain tissue similar to what was observed 
on H&E sections. Thus, T lymphocytes seemed to be the major cell population causing 
inflammation in VSV-WT injected animals. In contrast VSV-GP injected animals 
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Figure 5.3. Immunostaining for 
CD3. Black arrows indicate 
lymphocytes. Left panel of the 
top row shows PBS treated brain 
tissue (A). Two panels of the 
center row show VSV-GP 3 days 
p.i. (B) and VSV-GP 7days p.i. 
(C). Two panels at the bottom 
show VSV-WT 3 days p.i. (D) 
and VSV-WT 7 days p.i. (E). 
VSV-WT brains showed a strong 
infiltration of CD3 positive 
lymphocytes around vessels and 
in the brain tissue. In contrast 
VSV-GP brains tissue showed 
only few CD3 positive 
lymphocytes around vessels and 
in the brain. Infiltration of 
lymphocytes was almost absent in 
PBS injected animals. 
(Magnification: ×20). [Scale bars: 
100 µm] 
 
showed only few CD3 positive lymphocytes around vessels and in the brain. Infiltration 
of lymphocytes was almost absent in PBS injected animals (Figure 5.3 A). 
Quantification of the number of CD3 positive cells at day 3 p.i. revealed 48.2 ± 19.2 
lymphocytes for VSV-WT infected brains, while VSV-GP infected brains showed 
significantly less infiltration of lymphocytes (5 ± 4.2; p<0.0001; Figure 5.4). At day 7 p.i. 
a strong reduction of the number of lymphocytes was observed in VSV-WT injected 
animals (10.5± 10.9) compared to day 3 p.i. Also less infiltration of lymphocytes in VSV-
GP infected brains was observed from 3 to 7 days p.i. The difference of the VSV-GP 
group compared to the control group (PBS injected) at both days p.i. was not statistically 
significant (p=0.0911) indicating that VSV-GP did not induce a significant T-cell 
response (Figure 5.4). 
To analyze whether the resident immune cells of the brain, microglial cells, are 
participating in the inflammatory response, we stained sections for CD11b, a microglial 
marker. VSV-WT injected animals showed a slightly stronger activation of microglia  
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Figure 5.4. The amount of lymphocytes was quantified at 3 and 7 days p.i. in VSV-GP and VSV-
WT. 10 random microscopic fields were counted in ×20 magnification. The injection area was 
avoided. Significantly less lymphocytes were counted in VSV-GP infected animals at day 3 p.i. 
compared to VSV-W (p<0.0001). A strong reduction in the number of lymphocytes was observed 
from 3 days p.i. to 7 days p.i. in VSV-WT (p<0.0001). T cell counts of VSV-GP compared to the 
control group were not statistically significant (p =0.0911). ( * ) p<0.0001. 
 
 
around vessels and in the brain tissue compared do VSV-GP injected animals at day 3 p.i. 
(Figure 5.5 D and B). At day 7 p.i., the difference in quantity of microglial cells was even 
more evident (Figure 5.5 C and E). PBS injected animals showed only a few single 
microglial cells throughout the sections (Figure 5.5 A).  
Quantification of microglial cells revealed similar results, which was analyzed from 
immunohistochemical stainings. The number of microglial cells was 13.2 ± 5 for VSV-
WT at day 3 p.i., while VSV-GP showed significantly less microglial cells 3 days p.i. 
(3.9 ± 3; p<0.0001; Figure 5.6). Interestingly reduction of the microglials was not very 
significant from day 3 to day 7 p.i. in VSV-WT (9.4 ± 10.8; p=0.3889). The microglial 
cell count for VSV-GP compared to control was not statistically significant (p=0.6549; 
Figure 5.6) at both days p.i. 
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Figure 5.5. Immunostaining for 
CD11b (macrophage-1 antigen). 
Black arrows indicate microglia 
cells which show a strong 
immunostaining. Left panel of the 
top row shows PBS treated brain 
tissue (A). Two panels of the 
center row show VSV-GP 3 days 
p.i. (B) and VSV-GP 7days p.i. 
(C). Two panels at the bottom 
show VSV-WT day 3 p.i. (D) and 
VSV-WT day 7 p.i. (E). VSV-WT 
brain tissues showed a stronger 
activation of microglia around 
vessels and in the brain tissue 
compared do VSV-GP injected 
animals at day 3 p.i. At day 7 the 
difference in quantity of microglial 
cells was even more evident. 
(Magnification: ×20). [Scale bars: 
100 µm]. 
 
 
Figure 5.6. The number of microglial cells was determined by light microscopy. 10 random 
microscopic fields were counted, the area around the injection site was not considered. 
Significantly less microglial cells were observed in VSV-GP compared to VSV-WT at 3 days p.i. 
(p<0.0001). The numbers for VSV-WT at day 3 compared day 7 p.i. were not significantly 
different (p=0.3889). The numbers for VSV-WT compared to control group were significantly 
different (p<0.0001). The cell counts for VSV-GP compared to the control, were not statistically 
significant (p=0.6549). ( * ) p<0.0001. 
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5.1.3 Significant cell death of brain cells is only detected in VSV-wt injected mice  
 
In addition, we tested toxicity of both viruses by the use of cleaved Caspase-3 antibody, 
to investigate apoptosis of normal brain cells. By analyzing immunostained sections, 
more apoptotic cells were found in VSV-WT compared to VSV-GP injected mice brains 
both after 3 days and 7 days p.i. (Figure 5.7). No apoptotic cells were detected in PBS 
injected mice brains (Figure 5.7 A).  
Quantification of the number of apoptotic cells showed 7.9 ± 3.5 for VSV-WT, while 
less numbers of positive cells were counted for VSV-GP at 3 days p.i. (1 ± 1; p<0.0001; 
Figure 5.8). A strong reduction in the number of apoptotic cells was observed from 3 
days to 7 days p.i. in VSV-WT (1.2 ± 2.1; p<0.0001). The differences compared to the 
control group (PBS injected) were statistically significant both for VSV-WT (p<0.0001) 
and VSV-GP (p=0.0114; Figure 5.8) at day 3 p.i. 
 
 
 
 
Figure 5.7. 
Immunostaining for 
cleaved Caspase-3 (A-E). 
The pictures indicate 
more apoptotic cells in 
VSV-WT both after 3 and 
7 days post infection. Left 
panel of the top row 
shows PBS treated brain 
tissue (A). Two panels of 
the center row show 
VSV-GP 3 days p.i. (B) 
and VSV-GP 7days p.i. 
(C). Two panels at the 
bottom show VSV-WT 3 
days p.i. (D) and VSV-
WT 7 days p.i. (E). The 
amount of apoptotic cells 
were higher in VSV-WT 
compared to VSV-GP 
both after 3 days and 7 
days p.i.. No positive cell 
was detected in control 
group. (Magnification: 
×20). [Scale bars: 100 
µm]. 
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Figure 5.8. 10 different areas were counted for apoptotic cells by cleaved caspase-3 
immunostained sections. The injection site was avoided. Significantly less apoptotic cells were 
counted in VSV-GP compared to VSV-WT at 3 days p.i. (p<0.0001). Strong reduction of 
apoptotic cells was observed at day 3 to day 7 p.i. in VSV-WT (p<0.0001). The difference 
compared to the control group (PBS injected) was statistically significant both for VSV-WT 
(p<0.0001) and VSV-GP (p=0.0114). ( * )p<0.0001. 
 
We extended these findings by examining cell death using the TUNEL assay. The 
TUNEL assay aims at detecting fragmented DNA as indicator of apoptotic events. Also 
with this method, we found more apoptotic cells in the VSV-WT compared to the VSV-
GP samples both after 3 days and 7 days p.i (Figure 5.9). No positive cells were detected 
in the control group (Figure 5.9 A). Normal brain tissue, which was treated with DNase 
but without transferase used as negative control (Figure 5.9 B). 
Figure 5.10, displays the quantification of apoptotic cells in the TUNEL assay. 4.8 ± 
2.7 apoptotic cells were counted for VSV-WT at day 3 p.i., while VSV-GP infected 
brains showed significantly less apoptotic cells (1.6 ± 2.1; p<0.0001; Figure 5.10). At day 
7 p.i. a strong reduction of the number of apoptotic cells was observed for VSV-WT (1.9 
± 1.2) compared to day 3 p.i. Less apoptotic cells were seen in VSV-GP infected brains at 
day 7 compared to day 3 p.i. A significant decrease in the number of apoptotic cells was 
observed from 3 days p.i. infection to 7 days p.i. in VSV-WT (p<0.0001). The numbers 
were significantly different for both VSV-WT (p<0.0001) and VSV-GP compared to the 
control group (p=0.0281; Figure 5.10). 
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Figure 5.9. TUNEL assay on 
paraffin sections of mouse brains (A-
F). Shown are VSV-WT 3 days p.i. 
(E), VSV-GP 3 days p.i (C), VSV-
WT 7 days p.i. (F), VSV-GP 7days 
p.i. (D), control (A) and negative 
control (B, treated with DNase but 
without transferase). Higher cell 
numbers in the VSV-WT compared 
to the VSV-GP samples both after 3 
days and 7 days p.i. No positive cells 
were detected in control group. 
(Magnification: ×20).  [Scale bars: 
100 µm]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. The number of dead cells was determined by TUNEL assay, counting 10 different 
microscopic fields, the area around injection site was avoided. Significantly less apoptotic cells 
cells were counted for VSV-GP compared to VSV-WT at 3 days p.i. (p<0.0001). Significant 
reduction of dead cells was observed from day 3 to day 7 p.i. in VSV-WT (p<0.0001). Numbers 
were significantly different for both VSV-WT (p<0.0001) and VSV-GP compared to control 
group (p=0.0281). ( * ) p<0.0001. 
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5.2 Infection of neurons is only detected in VSV-WT injected mice 
 
To analyze the tropism of both vectors for normal brain cells, we used mouse brains 
infected with VSV-WT and VSV-GP delivering GFP in order to identify infected cells. 
We received fixed brain tissue from our collaborator, who performed the injection 
experiments (Alexander Muik, Frankfurt, Germany). The brain tissue was then frozen 
and cryosections were prepared as described in the Methods. Neurons were stained with 
anti-NeuN and astrocytes with anti-glial fibrillary acidic protein (anti-GFAP). The GFP 
signal was enhanced by staining with an anti-GFP antibody and sections were analyzed 
by confocal laser scanning microscopy.  
By analyzing serial sections, we observed that VSV-WT transduced NeuN-positive 
neurons (Figure 5.11) in several areas, while we did not find any glial fibrillary acidic 
protein (GFAP)-positive cells infected. This indicates that neurons are the primary targets 
of VSV-WT.  When screening sections from VSV-GP infected brains we could not detect 
any GFP positive cells even after staining with anti-GFP antibodies. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11.  A representative microscopic field from VSV-WT infected normal brain cells in 
vivo (A-C). Mouse brains were first fixed in 4%Paraformaldehyde/PBS solution overnight and 
then incubated in 30% sucrose/PBS solution for three days at 4 ْC. Coronal slices of mouse brains 
were prepared. Neurons were stained with anti-NeuN. Anti-GFP antibody was used to enhance 
the GFP signal indicating virus infection. (A) GFP, (B) NeuN, (C) Overlay. (Magnification: ×40). 
[Scale bars: 100 µm]. 
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5.3 Experimental brain tumors are efficiently transduced with VSV-GP 
 
As VSV-GP did not infect normal brain cells and did not show neurotoxicity either, this 
vector is a promising candidate to be used for gene therapy of brain tumors.  To assess 
the ability of replication-competent VSV (VSV-GP) to infect and replicate within brain 
cancer cells, recombinant viruses were administered intravenously to mice harbouring 
U87 gliomas. The intravenous approach was used in order to test the potential of VSV-
GP to enter the brain and infect tumor cells upon systemic delivery. The tumor cells were 
transduced with DsRed, while the virus packaged GFP in order to identify infected tumor 
cells by fluorescence. This experiment was performed by our collaborator (Alexander 
Muik, Frankfuert, Germany) and we got fixed brain tissue to analyze. 3 days p.i 
histological slides were prepared for confocal microscopic analysis to determine infection 
efficacy of VSV-GP. By analyzing the tumor area (DsRed positive), we detected efficient 
infection of tumor cells by VSV-GP virus (GFP) (Figure 5.12). This demonstrates that 
the virus can even home to the brain after systemic delivery and specifically infect the 
tumor cells. Normal brain cells were not transduced as also observed in the previous 
experiment. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Distribution of intravenously administered recombinant vesicular stomatitis virus 
(VSV-GP) expressing green fluorescent protein (GFP) in U87 tumors xenografted in the brain of 
immunodeficient mice. (A) GFP, (B) DsRed positive tumor mass, (C) overlay. (Magnification: 
×40). [Scale bars: 100 µm]. 
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6 Discussion 
 
In most gene therapy studies, a "normal" gene is inserted into the genome to replace an 
"abnormal," disease-causing gene. To treat a disease or correct a genetic deficiency, a 
carrier molecule called a vector must be used to deliver the therapeutic gene to a certain 
cell type. The goal in using gene therapy for the treatment of cancer is to develop new 
agents/viruses that have a high killing potency for malignant cells and less pathogenicity 
to normal cells. 
       To increase specificity of gene delivery, different strategies have been developed: (1) 
transcriptional targeting by using Adenovirus and Herpes simplex virus (61, 62); (2) 
cellular targeting by Adenovirus and Herpes simplex virus (63, 64); (3) Attenuation by 
deletion of viral genes or gene fragments of Adenovirus, Herpes simplex virus, Vaccinia 
virus, Poliovirus and Measles virus (65-70). However, the improvement of tumor 
specificity is often associated with a decrease in efficacy. Therefore, still better methods 
are warranted that can improve both, efficacy and specificity of killing/gene transfer. 
Oncolytic (onco=cancer; lytic=killing) viruses provide a promising tool for gene 
therapy, since they are innocuous, non-disease causing, replication competent viruses, 
which can replicate in and kill a large amount of human tumor cells (44). They may keep 
their tumor selectivity in attenuated forms as well as wild-type forms. Further, tumor-
selectivity can be provided by engineering of the viral genes (71). 
The most attractive approach to increase tumor-selectivity is to use viruses that 
possess inherent tumor-selectivity. A good example is vesicular stomatitis virus (VSV), 
which is highly sensitive to inhibition by interferon. Thus normal cells remain almost 
intact from infection while tumor cells which have deficiency in the Interferon (IFN) 
antiviral signaling network are rapidly eradicated. However, VSV is neurotoxic which 
certainly limits its application for brain tumors or brain-related diseases. The 
neurotoxicity is related to the VSV glycoprotein, which is critical for virus entry into the 
cells (51). Thus the pseudotyping of VSV with the glycoprotein of LCMV, which has 
been shown to spare infection of neurons (54), might be a promising approach to 
eliminate neurotoxicity. Therefore, in this thesis wild-type VSV vectors and VSV- 
pseudotyped with glycoprotein of LCMV were compared. 
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6.1 Immune responses to intracerebral VSV-WT and VSV-GP infections 
We have investigated the immune responses following infection of mouse brains with 
VSV and VSV pseudotyped with glycoproteins of LCMV. We identified CD3+ T cells 
and CD11b+ microglia as major cell populations causing inflammation in VSV-WT 
injected mice. Similar results have been obtained in previous studies (72, 73). In addition 
to T cells, the authors in the study by Christian et al. identified NK cells as contributors 
to the inflammatory response (72). In the study by Bi et al. the authors found that 
production of nitric oxide, an innate immune mechanism, also participated in the immune 
response (73). Interestingly, in the present study the quantity of immune cells decreased 
from 3 days to 7 days p.i., although mice normally succumb 7-10 days after infection 
(Muik et al. unpublished observation). A hypothesis could be that the cytotoxic effect of 
the virus comes after the peak of inflammation and induces a cytotoxic edema in the 
brain, which is lethal. This is supported by our observation, that the brain tissue showed 
edema at 7 days p.i., which was not observed at 3 days p.i. 
In contrast, CNS infection with VSV-GP, which has not been studied in detail before, 
showed only a minor inflammatory response at the injection site and only few CD3+ T 
cells at distant sites. Thus, this virus did not induce a significant immune response 
compared to VSV-WT. This is also reflected by a survival study where intracerebral 
injections of VSV-WT caused death of all mice even at low viral titers (10E2), while all 
mice injected with VSV-GP even at high titers (10E7) survived (Muik et al., unpublished 
observations).  
 
6.2 Cytopathic effect of VSV-WT vectors for brain cells 
In our study, we observed that VSV-WT induced considerable cell death in normal brain 
cells by using cleaved Caspase-3 and TUNEL immunostainings. In contrast, VSV-GP 
infection induced apoptosis in only few single cells, which were statistically significant 
much less compared to VSV-WT infected brains. Caspase-3 is a key molecule in the 
apoptotic pathway of cells and its cleavage clearly indicates that this pathway is activated 
(74). The TUNEL assay represents a method, which detects DNA fragmentation as a 
result of the activation of apoptotic signaling cascades (75). Thus these two methods 
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detect different steps in the apoptotic pathway and thus taken together clearly indicate 
that VSV-WT, in contrast to VSV-GP, induces apoptosis in normal brain cells. 
The strong cytopathic effect of VSV has been related to the viral glycoprotein and the 
viral matrix protein. Moreover, it was found that these two substantial proteins trigger 
apoptosis through distinct pathways. Apoptosis was associated with the formation of 
syncytia between infected cells (giant polynucleated cells) suggesting that the fusogenic 
properties of the VSV-G protein was involved (76). This fusogenic protein undergoes a 
reversible conformational change upon contact with the acidic milieu of the Golgi 
apparatus in the secretory pathway. Thus, it is its fusion active form when it reaches the 
plasma membrane and therefore is able to perform cell–cell fusion (77, 78). In all 
fusogenic viruses the fate of resulting syncytia is apoptosis (79-82). 
Other studies observed that the amino acid substitutions M51R, V221F and S226R in 
the M protein, which inhibit both cellular transcription and nucleocytoplasmic mRNA 
transport, probably are responsible for cytotoxic properties of VSV (83-89). However, the 
results in this thesis clearly show that exchange of the VSV glycoprotein by a 
glycoprotein of a different virus can eliminate neurotoxicity, which indicates that the 
observed cytotoxic properties of the Matrix protein (M) are strongly dependent on a 
functional VSV glycoprotein and most likely on its fusion activity (76). 
 
 
6.3 Neurons are a target of VSV-WT, but not VSV-GP vectors 
Infection of mouse brains with VSV-WT and VSV-GP viruses delivering GFP enabled us 
to analyze which cell types are infected by the different virus strains. While VSV-WT 
showed infection of neurons, no infection of brain cells with VSV-GP could be detected. 
In previous studies using the glycoprotein of VSV-G pseudotyped with lentiviral vectors, 
Miletic et al. also showed infection of neurons, while lentiviral vectors pseudotyped with 
LCMV-GP did not infect neuronal cells, but few glial cells (58).  This was confirmed by 
another recent study using replication deficient VSV (54). 
The tropism of viruses has been attributed to the cellular receptors. VSV shows a very 
broad cell tropism and replicates rapidly in various cell lines that are derived from 
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different species and tissues. The presence of phosphotidylserin (a universal component 
of cell-surface membrane) correlates with the extensive tissue tropism of VSV (82). 
The glycoprotein of LCMV binds with high affinity to alpha-dystroglycan, a receptor on 
the cell membrane. Alpha-dystroglycan is a dystrophin-associated glycoprotein, which is 
widely expressed in most tissues (54, 90). Thus, it is somewhat surprising that LCMV is 
sparing neurons as alpha-dystroglycan is also expressed on neuronal and glial cells (54). 
One hypothesis could be that LCMV needs a co-receptor to infect cells which is not 
present on neurons. In this regards, some studies have shown that certain LCMV variants 
inefficiently interact with alpha-dystroglycan and also infect alpha-dystroglycan-negative 
cells (91). Further it has been observed that LCMV upon injection into the brain 
primarily infects glial cells and at later time points when the infection becomes persistent 
spreads to neurons (92). The infection of neurons might then be dependent on certain 
properties of the LCMV which are not present when only the glycoprotein is used for 
pseudotyping with a different virus.  
Although we did not observe infection of normal brain cells by VSV-GP, we might 
have missed infection of a few glial cells as this has been reported before (54). Also the 
identification of a few apoptotic cells by cleaved Caspase-3 and TUNEL staining which 
were significantly more compared to PBS injected controls indicates that a few brain 
cells were infected and killed by the virus. However, these cells seem not to be neuronal 
cells and the effect is not toxic enough to induce symptoms or even lethality. 
 
 
6.4 Efficiently transduction of brain tumors by VSV-GP 
 
In the majority of clinical trials performed so far, oncolytic viruses have been 
administered via intratumoral injection. A smaller number of studies have examined 
regional or intravenous delivery. An ideal oncolytic virus for cancer should show 
effective spread to multiple sites within the tumor upon systemic delivery or it should be 
modifiable to be efficient in tumor targeting. This has been shown in the present thesis. 
Following intravenous administration of the recombinant virus VSV-GP, efficient and 
specific infection of brain cancer cells was observed. 
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In a study that was conducted in 2006, the effectiveness and toxicity of VSV ∆ M51, 
which contains a single – amino acid deletion in the M protein was evaluated in vitro and 
in vivo. VSV ∆ M51 infected and killed 14 different glioma cell lines and when 
administered intravenously to nude mice bearing human gliomas, significant regression 
of tumors was observed. Interestingly no evidence of toxicity was found, probably due to 
modification of the M protein (93). 
In another study the efficacy of two oncolytic viruses, myxoma virus (MV) and an 
attenuated vesicular stomatitis virus VSV ∆ M51 were compared in vivo with using the 
same dose and intratumoral administration for both viruses. Remarkable shrinkages were 
observed for both viruses when they injected directly into the tumor mass. Looking at 
details confirmed VSV ∆ M51 was somewhat more effective than MV (94). However, 
the efficacy of these viruses might not be sufficient for the human situation, as the 
mutated M protein significantly reduces the replication and lytic potential of the virus. In 
contrast, VSV-GP viruses used in the presented thesis still have the full replication and 
lytic abilities.  
A drawback of systemically delivered virus for glioblastoma therapy is pointed out by 
Xueqing Lun et al. First, the spread of the virus within the tumor may be limited to due 
the immune system’s response. Secondly, although the leaky blood-brain barrier of the 
main tumor mass allows the virus to enter the tumor, invasive glioma cells might escape 
therapy as they remain in areas where the blood-brain-barrier is still intact (93). Thus, the 
future animal experiments with clinically more relevant glioma models and clinical 
studies in patients might show which route of delivery will be most efficient in killing 
glioblastoma cells with oncolytic vectors. 
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6.5 Conclusion  
 
In summary, replication competent LCMV-GP pseudotyped VSV vectors mediate 
specific and efficient infection of glioblastoma in vivo upon systemic delivery without 
signs of neurotoxicity. In contrast, VSV-WT vectors are neurotoxic and induce a T-cell 
mediated immune response with infiltration of CD3 positive T cells and activation of 
CD11b positive microglia. Analysis of tropism for normal brain cells explains the 
difference of these two vectors regarding neurotoxicity as VSV-WT vectors infect 
neurons, while VSV-GP vectors do not infect normal brain cells. Thus VSV-GP vectors 
are promising candidates for future gene therapy applications of brain tumors due to their 
ability to specifically infect and replicate in brain tumor cells.   
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7 Future perspectives 
 
This work shows that VSV-GP oncolytic vectors efficiently and specifically infect 
glioma cells in vivo without causing significant neurotoxicity. However, future studies in 
clinically relevant animals are warranted in order to evaluate the efficacy of this vector in 
angiogenic as well as invasive tumor areas. These studies should also clarify whether a 
systemic or local delivery will be more effective. The results of these future experimental 
studies will be an important basis for a potential clinical application of VSV-GP 
oncolytic vectors. 
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